DEA Schedules 4-Fluoroamphetamine as Top-Tier Illegal
Published Date: 6/3/2025
Proposed Rule
Summary
The DEA wants to put 4-fluoroamphetamine (4-FA) into Schedule I, meaning it’s now officially super illegal to make, sell, or use. This change helps the U.S. follow international drug rules and adds serious penalties for anyone caught with it. If this goes through, anyone handling 4-FA will face strict controls starting soon, with no money benefits but big legal risks.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Possession of 4‑FA becomes Schedule I crime
The DEA proposes putting 4‑fluoroamphetamine (4‑FA) into Schedule I. If finalized, anyone who possesses or uses 4‑FA would be subject to the regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances.
Manufacturers and sellers face strict controls
The proposal would impose Schedule I regulatory controls and administrative, civil, and criminal sanctions on people who manufacture, distribute, reverse distribute, import, or export 4‑FA. Businesses that handle 4‑FA would become subject to the full set of Schedule I restrictions and penalties.
Researchers and instructors subject to Schedule I rules
If finalized, people who engage in research, instructional activities, or chemical analysis with 4‑FA would be subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I substances. That means researchers and educators handling or proposing to handle 4‑FA must follow Schedule I controls.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-09983 — Designation of Propionyl Chloride as a List I Chemical
The DEA wants to add propionyl chloride to a special list of chemicals that need extra rules because it’s used to make illegal drugs like fentanyl. If this happens, anyone handling this chemical will have to follow strict regulations, no matter how much they have or if it’s mixed with other stuff. This change aims to stop bad guys from making dangerous drugs and will affect businesses right away.
Next: 2025-09991 — Rescission of Affirmative Fair Housing Marketing Regulations
The government is canceling rules that made housing programs fill out special fair housing marketing plans. This change affects anyone using FHA insurance or rental help programs and means less paperwork starting soon. It’s a move to simplify things without changing the goal of fair housing.